GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Straumann Holding AG (XSWX:STMN) » Definitions » Debt-to-EBITDA

Straumann Holding AG (XSWX:STMN) Debt-to-EBITDA : 2.09 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Straumann Holding AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Straumann Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF29 Mil. Straumann Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF383 Mil. Straumann Holding AG's annualized EBITDA for the quarter that ended in Dec. 2023 was CHF198 Mil. Straumann Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Straumann Holding AG's Debt-to-EBITDA or its related term are showing as below:

XSWX:STMN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.52   Med: 0.95   Max: 3.15
Current: 0.83

During the past 13 years, the highest Debt-to-EBITDA Ratio of Straumann Holding AG was 3.15. The lowest was 0.52. And the median was 0.95.

XSWX:STMN's Debt-to-EBITDA is ranked better than
58.6% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.235 vs XSWX:STMN: 0.83

Straumann Holding AG Debt-to-EBITDA Historical Data

The historical data trend for Straumann Holding AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Straumann Holding AG Debt-to-EBITDA Chart

Straumann Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 3.15 1.18 1.03 0.83

Straumann Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 - 1.48 - 2.09

Competitive Comparison of Straumann Holding AG's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Straumann Holding AG's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Straumann Holding AG's Debt-to-EBITDA falls into.



Straumann Holding AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Straumann Holding AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(28.943 + 383.41) / 494.172
=0.83

Straumann Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(28.943 + 383.41) / 197.786
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Straumann Holding AG  (XSWX:STMN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Straumann Holding AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Straumann Holding AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Straumann Holding AG (XSWX:STMN) Business Description

Traded in Other Exchanges
Address
Peter Merian-Weg 12, Basel, CHE, 4002
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company's core products are dental implants, and it holds roughly 30% of the global implant dentistry market, which is estimated to be worth roughly CHF 5.4 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.

Straumann Holding AG (XSWX:STMN) Headlines

No Headlines